Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center
Aim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We conducted a retrospective cross-sectional analysis...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/14/2/120 |
| _version_ | 1797476259694903296 |
|---|---|
| author | Bettina Wabbels Rolf Fimmers Peter Roggenkämper |
| author_facet | Bettina Wabbels Rolf Fimmers Peter Roggenkämper |
| author_sort | Bettina Wabbels |
| collection | DOAJ |
| description | Aim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We conducted a retrospective cross-sectional analysis at a university hospital. Patients with BEB and BoNT-A treatment were assigned to the Total Blepharospasm Group, patients with ≥21 onabotulinumtoxin-A injections to the Ona Long-Term Group. The Total Blepharospasm Group (<i>n</i> = 1940) included 33,933 BoNT-A injections. The age of patients at symptom onset was (mean ± SD) 58.0 ± 13.1 years, and 70.4% were female. The Ona long-term group (<i>n</i> = 234) included 10,632 onabotulinumtoxin-A injections. In this group, patients received 45.4 ± 22.9 injections with a mean dose of 22.2 IU ± 0.5. The duration of treatment was 12.6 ± 5.4 years, ranging from 2.9 to 30.0 years. The effect–duration–dose quotient did not change during long-term treatment. The observed side effects were comparable in type and frequency to other studies, even with the (ultra-)long treatment with onabotulinumtoxin-A. Our results, based on one of the largest patient populations and a treatment duration of up to 30 years, impressively demonstrate that onabotulinumtoxin-A is a safe and effective therapy for essential blepharospasm, even in the ultra-long term. |
| first_indexed | 2024-03-09T20:55:27Z |
| format | Article |
| id | doaj.art-645aa3c06e24490c8f228d5cf4c45307 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-09T20:55:27Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-645aa3c06e24490c8f228d5cf4c453072023-11-23T22:21:43ZengMDPI AGToxins2072-66512022-02-0114212010.3390/toxins14020120Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care CenterBettina Wabbels0Rolf Fimmers1Peter Roggenkämper2Department of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Street 2, D-53127 Bonn, GermanyInstitute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, D-53127 Bonn, GermanyDepartment of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Street 2, D-53127 Bonn, GermanyAim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We conducted a retrospective cross-sectional analysis at a university hospital. Patients with BEB and BoNT-A treatment were assigned to the Total Blepharospasm Group, patients with ≥21 onabotulinumtoxin-A injections to the Ona Long-Term Group. The Total Blepharospasm Group (<i>n</i> = 1940) included 33,933 BoNT-A injections. The age of patients at symptom onset was (mean ± SD) 58.0 ± 13.1 years, and 70.4% were female. The Ona long-term group (<i>n</i> = 234) included 10,632 onabotulinumtoxin-A injections. In this group, patients received 45.4 ± 22.9 injections with a mean dose of 22.2 IU ± 0.5. The duration of treatment was 12.6 ± 5.4 years, ranging from 2.9 to 30.0 years. The effect–duration–dose quotient did not change during long-term treatment. The observed side effects were comparable in type and frequency to other studies, even with the (ultra-)long treatment with onabotulinumtoxin-A. Our results, based on one of the largest patient populations and a treatment duration of up to 30 years, impressively demonstrate that onabotulinumtoxin-A is a safe and effective therapy for essential blepharospasm, even in the ultra-long term.https://www.mdpi.com/2072-6651/14/2/120blepharospasmbotulinum toxinlong-termoutcomeadverse events |
| spellingShingle | Bettina Wabbels Rolf Fimmers Peter Roggenkämper Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center Toxins blepharospasm botulinum toxin long-term outcome adverse events |
| title | Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center |
| title_full | Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center |
| title_fullStr | Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center |
| title_full_unstemmed | Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center |
| title_short | Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A—30 Years of Experience in a Tertiary Care Center |
| title_sort | ultra long term therapy of benign essential blepharospasm with botulinumtoxin a 30 years of experience in a tertiary care center |
| topic | blepharospasm botulinum toxin long-term outcome adverse events |
| url | https://www.mdpi.com/2072-6651/14/2/120 |
| work_keys_str_mv | AT bettinawabbels ultralongtermtherapyofbenignessentialblepharospasmwithbotulinumtoxina30yearsofexperienceinatertiarycarecenter AT rolffimmers ultralongtermtherapyofbenignessentialblepharospasmwithbotulinumtoxina30yearsofexperienceinatertiarycarecenter AT peterroggenkamper ultralongtermtherapyofbenignessentialblepharospasmwithbotulinumtoxina30yearsofexperienceinatertiarycarecenter |